Carcinoembryonic antigen as a vaccine target

References

• Benchimol S, Fuks A, Jothy S et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell57, 327–332 (1989).
   PubMed Web of Science ®Google Scholar
• Kent SJ, Zhao A, Best SJ et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol.72, 10180–10188 (1998).
   PubMed Web of Science ®Google Scholar
• Taylor J, Trimarchi C, Weinberg R et al. Efficacy studies on a canarypox rabies recombinant virus. Vaccine9, 190–193 (1991).
   PubMed Web of Science ®Google Scholar
• Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int. J. Cancer48, 900–907 (1991).
   PubMed Web of Science ®Google Scholar
• Kantor J, Irvine K, Abrams S et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl Cancer Inst.84, 1084–1091 (1992).
   PubMed Web of Science ®Google Scholar
• Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst.87, 982–990 (1995).
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabzevari H, Yafal AG et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res.59, 5800–5807 (1999).
   PubMed Web of Science ®Google Scholar
• Von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B 7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res.6, 2219–2228 (2000).
   PubMed Web of Science ®Google Scholar
• Lorenz MG, Kantor JA, Schlom J et al. Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus. Hum. Gene Ther.10, 623–631 (1999).
   Google Scholar
• Uzendoski K, Kantor JA, Abrams SI et al. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum. Gene Ther.8, 851–860 (1997).
   PubMed Web of Science ®Google Scholar
• Hodge JW, Schlom J. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res.59, 5106–5111 (1999).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Hawkins MJ, Tsang KY et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol.17, 332–337 (1999).
   PubMed Web of Science ®Google Scholar
• Hodge JW, McLaughlin JP, Kantor JA. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T cell immunity and antitumor responses. Vaccine16, 759–768 (1997).
   Web of Science ®Google Scholar
• Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox to elicit anti-carcinogenic antigen immune responses. J. Clin. Oncol.18, 3964–3973 (2000).
   PubMed Web of Science ®Google Scholar
• Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self antigen and antitumor activity. Cancer Res.62, 5770–5777 (2002).
   PubMed Web of Science ®Google Scholar
• von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res.6, 2219–2228 (2000).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox –CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte–macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol.23, 720–731 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor-Papadimitriou J, Burchell JM, Plunkett T et al. MUC1 and the immunobiology of cancer. J. Mammary Gland Biol. Neoplasia7, 209–221 (2002).
   PubMed Web of Science ®Google Scholar
• Hiltbold EM, Alter MD, Ciborowski P et al. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell. Immunol.194, 143–149 (1999).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim-Schulze S, Manson K et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J. Transl. Med.5, 60 (2007).
   PubMed Web of Science ®Google Scholar
• Gulley JK, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxvirus-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res.14(10), 3060–3069 (2008).
   PubMed Web of Science ®Google Scholar
• Jerne NK. Towards a network theory of the immune system. Ann. Immunology125C, 373–389 (1974).
   PubMedGoogle Scholar
• Lindenmann J. Speculations on idiotypes and homobodies. Ann. Immunology124, 171–184 (1973).
   PubMedGoogle Scholar
• Bhattacharya-Chatterjee M, Mukerjee S, Biddle W et al. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J. Immunol.145(8), 2758–2765 (1990).
   PubMed Web of Science ®Google Scholar
• Foon KA, Chakraborty M, John WJ et al. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Invest.96(1), 334–342 (1995).
   PubMed Web of Science ®Google Scholar
• Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin. Cancer Res.3(8), 1267–1276 (1997).
   PubMed Web of Science ®Google Scholar
• Zbar AP, Thomas H, Wilkinson RW et al. Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a Phase I study. Int. J. Colorectal Dis.20(5), 403–414 (2005).
   PubMed Web of Science ®Google Scholar
• Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol.17(9), 2889–2895 (1999).
   PubMed Web of Science ®Google Scholar
• Posner MC, Niedzwiecki D, Venook AP et al. A Phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann. Surg. Oncol.15(1), 158–164 (2008).
   PubMed Web of Science ®Google Scholar
• Saha A, Chatterjee SK, Foon KA et al. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Cancer Res.63(11), 2844–2854 (2003).
   PubMed Web of Science ®Google Scholar
• Saha A, Baral RN, Chatterjee SK et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol. Immunother.55(5), 515–527 (2006).
   Google Scholar
• Saha A, Chatterjee SK, Foon KA et al. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res.67(6), 2881–2892 (2007).
   PubMed Web of Science ®Google Scholar
• Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst.87(13), 982–990 (1995).
   PubMed Web of Science ®Google Scholar
• Morse MA, Deng Y, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res.5(6), 1331–1338 (1999).
   PubMed Web of Science ®Google Scholar
• Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA98(15), 8809–8814 (2001).
   PubMed Web of Science ®Google Scholar
• Weihrauch MR, Ansén S, Jurkiewicz E et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res.11(16), 5993–6001 (2005).
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Frödin JE, Jeddi-Tehrani M et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin. Cancer Res.10(10), 3273–3281 (2004).
   PubMed Web of Science ®Google Scholar
• Morse MA, Nair SK, Mosca PJ et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest.21(3), 341–349 (2003).
   PubMed Web of Science ®Google Scholar
• Conry RM, Curiel DT, Strong TV et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res.8(9), 2782–2787 (2002).
   PubMed Web of Science ®Google Scholar
• Cole DJ, Baron PL, O’Brien P et al. Phase I study of recombinant carcinoembryonic antigen (CEA) vaccinia virus vaccine with post vaccination carcinoembryonic antigen peptide (CAP-1) boost. Clin. Lung Cancer1(3), 227–229 (2000).
   Google Scholar